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COULD BIOBANKING BE A MEANS TO INCLUDE 
"HEAL TH CARE HA VE-NOTS" IN THE GENOMICS 
REVOLUTION? 
Michael J. Malinowski* 
INTRODUCTION 
The United States invests tens of billions of taxpayer dollars in basic 
research annually, 1 while clinical research is financed largely by the 
commercial sector and with a focus on market consumption of resulting 
products.2 Populations without economic means or a loud political 
voice traditionally have been marginalized in clinical research, 
including children, 3 women, 4 and many minority groups. 5 For the 
• J.D. Yale Law School 1991; B.A., summa cum laude, Tufts University 1987. Ernest 
R. and Iris M. Eldred Endowed Professor of Law, Paul M. Hebert Law Center, 
Louisiana State University (LSU), and Co-Founder and Associate Director, Program 
in Law, Science, and Public Health. The author would like to thank Daven Williams 
and Reginald Tucker for their valued research assistance. 
1 Investment through NIH alone was $28 billion in 2004, and $28.6 billion has been 
budgeted for 2005. Jonathan Weisman, 2006 Cuts in Domestic Spending on Table, 
WASH. POST, May 27, 2004, at Al; Drug Development: Medicine Price Hike 
Highlights Controversy of Government Funding Drug Research, HEALTH & MED . 
'jYK., June 14, 2004, at 325. 
See generally PHRMA, PHARMACEUTICAL INDUSTRY PROFILE 2005 (2005) 
[hereinafter PHRMA], available at 
http://www.phrma.org/publications/publications//2005-03-17.1143.pdf. Gordon 
Duval, Institutional Conflicts of Interest: Protecting Human Subjects, Scientific 
Integrity, and Institutional Accountability, 32 J.L. MED & ETHICS 613 (2004); 
Thomas Bodenheimer, Uneasy Alliance-Clinical Investigators and the 
fharmaceutical Industry, 342 NEW ENG. J. MED. 1539 (2000). 
The U.S. Government has introduced an incentive, a quid pro quo, to inspire 
pharmaceutical companies to gather clinical data on the impact of their products on 
children through the pediatric exclusivity. Janet Fricker, Too Much Too Young, NEW 
SCIENTIST, Feb. 20, 1999, at 18. Pharmaceutical sponsors are granted patent 
extensions in exchange for compiling this data. See id. A dearth of pediatric clinical 
data for pharmaceuticals routinely prescribed to children inspired this reform. See id 
See also Jennifer Powell, Law, Docs Eye Safer Drugs for Kids, BOSTON HERALD, 
!une 10, 2001, at 27. 
See generally NIH, Office of Extramural Research, NIH Policy and Guidelines on 
the Inclusion of Women and Minorities as Subjects in Clinical Research, available at http:/ !grants.nib. gov/ grants/funding/ women_ min/ guidelines_amended_ l 0 _200 l .h tm. 
Supportive data is available via the Office on Women's Health, Department of Health 
and Human Services, http://www.4woman.gov/owh/ and the "Women's Health" 
Pages of the National Institutes of Health Internet site, 
http:/ /health .nib. gov/ search. asp/28. 
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purposes of this article, these groups will be referred to as "Health Care 
Have-Nots" ("HCHNs"). Some of the HCHNs have been exploited in 
c linical research studies, including studies sponsored and even directly 
conducted by the U . S .  government.6 The Food and Drug 
Administration ("FDA") has routinely approved and overseen human 
c linical trials performed without demographic representation from the 
HCHNs and, subsequently, authorized the market entry of resulting 
products as treatments for diseases prevalent in the general population 
7 and among HCHNs. 
5 See generally, AHRQ's Role in Eliminating Racial and Ethnic Disparities in Health 
Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources, 
107th Cong. ( May 21, 2002) (statement of Dr. Carolyn Clancy, Acting Director, 
AHRQ), available at http://www.hhs.gov/asl/testify/t02052 l .html. See generally 
INSTITUTE OF MEDICINE, UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC 
DISPARITIES IN HEALTHCARE (Brain D. Smedley et al. eds., 2003), available at 
http://www.iom.edu/report.asp?id=4475 [hereinafter UNEQUAL TREATMENT]; 
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ) , STRATEGIES FOR 
IMPROVING MINORITY HEAL TH CARE QUALITY (2004 ) , available at 
http://www.ahrq.gov/downloads/pub/evidence/pdf/minqual/minqual.pdf 
(last visited Sept. 23, 2005) [hereinafter AHRQ REPORT]; AHRQ, Fact Sheet: 
Addressing Racial and Ethnic Disparities in Health Care, available at 
http://www.ahrq.gov/research/disparit.htm [hereinafter Fact Sheet]. The IOM Report 
findings are damning: 
The report says a large body of research underscores the existence of 
disparities. For example, minorities are less likely to be given 
appropriate cardiac medications or to undergo bypass surgery, and are 
less likely to receive kidney dialysis or transplants. By contrast, they 
are more likely to receive certain less-desirable procedures, such as 
lower limb amputations for diabetes and other conditions. 
U nequal Treatment: Confronting Racial and Ethnic Disparities in Health Care, 
Institute of M edicine, http://www.iom.edu/?id=l5962 (last visited Jan. 14, 2006). 
6 Most notable is the Tuskegee syphilis project funded by the Public Health Service 
over three decades. See generally Nancy Jecker, Tuskegee's Truths: Rethinking the 
Tuskegee Syphilis Study, 343 NEW ENG J. MED. 1581 (2000); Patricia A. King, 
Reflections on Race and Bioethics in the United States 14 HEALTH MATRIX 149 
(2004); Barbara L. Bernier, Class, Race and Poverty: 
'
Medical Technologies and 
�oci�political C�oic�s, 11 HARV. BLACKLETTERL. J. 115, 122-125 (1994). 
This observat10n is representative of the U.S.' s free market system, which has 
proven to be extremely productive. See generally PHRMA, supra note 2. Drug 
sponsors are allotted free-market discretion, and, subsequent to approval of their 
products, physicians are allotted discretion to prescribe off-label. "In fact, Congress 
re�ognized the realities of off-label prescribing when it authorized Medicaid 
reimbursement of pharmaceuticals for uses that appear in certain medical compendia, 
even if the FDA has not approved that use for inclusion in labeling." See Lars Noah, 
Informed Consent and the Elusive Dichotomy Between Standard and Experimental 
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Contemporary biomedical research and development ("R&D") 
in the U.S. is centering on the genomics revolution-an initiative to 
understand gene and protein function as a means to intervene in the 
biological pathways of disease and medical treatment, and to develop 
more effective human health therapies.8 Thus far, genomics has been 
adding dimensions of precision to human health care product 
development, fractioning traditional disease groups and markets,9 and 
raising health care costs.10 Bioinformatics, the combination of 
information technology and biology, is the primary means to make 
medical sense out of the map of the human genome, and 
bioinformatics capabilities continue to expand. 11 Consequentially, the 
demand for access to human biological samples and medical 
information never has been greater, and this demand has given rise to 
ambitious biobanking initiatives-efforts to compile organized 
collections of DNA samples and accompanying medical information 
from human populations. 12 
Therapy, 28 AMER. J. L. AND MED. 361, 398 (2002) (citing 42 U.S.C. §§ 1396r-
8(k)(6), 1395x(t)(2)(B) (2000)) (authorizing Medicare reimbursement for off-label 
uses of oncology drugs if consistent with medical compendia or the peer-reviewed 
literature). 
8 See generally Symposium, The G enomics R evolution? Science, Law, and Policy , 66 
LA. L. REV. 1 (2006) [hereinafter Genomics Revolution] (live conference transcripts 
on file with author). 
9 Michael J. Malinowski, Taking Genomics to the BioBank: Access to Human 
Biological Samples and Medical Infonnation, 66 LA. L. REv. 43, 46 n.15 (2006). 
10 Given the precision introduced b y  genomics, smaller groups will have to shoulder 
resulting R&D drug costs. See generally Jeffrey L. Moe, Commercialization 
Considerations for Individualized Diagnostic and Drug T herapies Resulting from 
Pharmacogenomics, 66 LA. L. REV. 103 (2005). This trend is likely to continue until 
technology evolves to enable actual elimination of diseases rather than turning them 
into chronically treated conditions. Michael McGinnis, Trends in Population Health­
are they influenced by medical and scientific advances? 66 LA. L. REV. 9, 19-20 
(2006). 
11 See generally Genomics Revolution, supra note 8; POPULATIONS AND GENETICS: 
LEGAL AND SOCIO-ETHICAL PERSPECTIVES (Bartha Maria Knoppers ed., 2003); Lars 
Noah, The Coming Phannacogenomics Revolution: Tailoring Drugs to Fit Patients' 
Genetic Profiles, 43 JURIMETRICS 1, 4-11 (2002); Michael J. Malinowski, Law, 
Policy, and Market Implications of Genetic Profiling in Drug Development, 2 
HOUSTON J. HEALTH L. & PoL'Y 231 (2003); PHRMA. supra note 2. Bioinformatics 
is the integration of biology and information technology to id�ntify �ene and protein 
structure and function, usually with the ultimate objective of discovenn� dru� targets. 
See D.E. Winickoff, Governing Population Genomics: Law, Bwethzcs, and 
Biopolitics in Three Case Studies, 43 JURIMETRICS 187, 189 (2003). . 
12 Biobanking is an extension of the practice for more than a century of collectm
g 
human biological materials and building repositories for research use. See generally 
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This article will explore the extent to which groups left out of 
the genomics revolution could gain access through biobanking. 1 3 The 
premise is that groups seeking access to the forefront of biomedical 
R&D might draw upon case studies and the technology transfer 
experiences of universities during the 1990s. This was a period of 
transition from historic division between academia and industry to 
intense integration of interests and collaborations among academia, 
industry, and government to advance commercial biotechnology. 14 The 
primary objeqtive of this article is to probe the implications of active 
biobanking by HCHNs. 
Part I of this article will present an overview of the state of 
healthcare finance in the U.S. and the realities of unequal health care 
access and treatment. The HCHNs will be identified, and the message 
is twofold. First, the costs of health care in the U.S. are rising and 
shifting, causing more people to be uninsured and underinsured.15 
Second, this trend threatens to exacerbate significant existing 
inequalities in access to health care based upon race and ethnicity.16 
Part I also will summarize the U.S. legacy of first exploitation and then 
relative exclusion of HCHN s in biomedical R&D. 
ALLEN BUCHANAN, An Ethical Framework for Biological Samples Policy, in 
NATIONAL BIOETHICS ADVISORY COMMISSION, RESEARCH INVOLVING HUMAN 
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE, VOLUME II 
C OMMISSIONED PAPERS, at B- 1 (2000) [hereinafter NBAC COMMISSIONED PAPERS], 
available at http://www.georgetown .edu/research/nrcbl/nbac/hbmll.pdf; Elisa 
Eiseman, Stored Tissue Samples: An Inventory of Sources in the United States, in 
NBAC COMMISSIONED PAPERS, supra, at D- 1 ;  David Korn, Contribution of the 
Human Tissue Archive to the Advancement of Medical Knowledge and the Public 
Health, in NBAC COMMISSIONED PAPERS, supra, at E-1 .  See Symposium, Regulation 
of Biobanks, 33 J. L. MED. & ETHICS 1 (Mark Rothstein & Bartha Knoppers eds., 
2005) [hereinafter Biobanks] (providing an excellent, timely treatment of 
biobanking). 
13 This article builds upon two collaborations with Professor Bartha Knoppers that 
involved written symposia. See generally Genomics Revolution, supra note 8; 
Biobanks, supra note 1 2. 
14 See Michael J. Malinowski, Technology Transfer and Development Agreements, in 
BIOTECHNOLOGY: LAW, BUSINESS, AND REGULATION § 3.02[C] ( 1 999). See 
generally Michael J. M alinowski, Institutional Conflicts and Responsibilities in an 
�ge of �cade-:rzic-Industry Alliances, 8 WIDENER L. SYMP. J. 47 (2001). . . Emily Fnedman, Health Insurance, the Uninsured and Hospitals: Coll1S1on 
Course, FRONTIERS HEALTH SERVICES MGMT., July 1 ,  2005, at 3; Thomas 
Bodenheimer, High and Rising Health Care Costs, 142 ANNALS OF INTERNAL MED. 
847 (2005). 
16 See supra notes 5, 25-34 and accompanying text. 
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Part II will shift focus to the present and future of biomedical 
R&D, which is centering on population genetics and biobanking. This 
discussion will introduce case studies that illustrate how some HCHN s 
are gaining access to the forefront of the genomics revolution through 
technology transfer and development in biobanking. Part II will 
introduce proposals to increase biobanking by HCHNs as a means to 
widen their access to both p articipation in genomics research and the 
resulting health care innovations. This discussion also will directly 
address the consequential implications of encouraging race-based 
research and medicine. The article concludes that biobanking presents 
an opportunity to increase positive participation of HCHNs in the 
genomics revolution and encourages embracing that opportunity, but 
with caution given the U.S. legacy of race-based medicine and research 
and the lingering presence of that legacy as documented by the IOM 
and the AH QR. 17 
I. THE HCHNS IN U.S. HE ALTH CARE AND 
BIOMEDIC AL R&D 
The state of health care finance in the U.S. is infamous and worsening: 
forty-five million people are uninsured, most of them working, and 
many millions more are underinsured; 1 8 costs are rising significantly 
and shifting from employers to employees; 19 a $62 trillion shortfall is 
projected for Medicare, due largely to the new prescription drug 
benefit; 2 0  states are slashing programs to offset their shortfalls;2 1 the 
Bush Administration is granting Medicare program waivers almost 
17 s 5 . ee supra notes 5, 2 -34 and accompanying text. 
18 Shannon S. Venable, A Call to Action: Georgia Must Adopt New Standard of Care, 
Licensure, Reimbursement and Privacy Laws for Telemedicine, 54 EMORY L.J. 1183, 
1183-1184 (2005). 
19 Anne D'lnnocenizo, Health Care Costs Continue to Shift, CHARLOTTE OBSERVER, 
Sept. 14, 2005, at 30; Glen Singer, Survey Shows Employers Will Shift Burden of 
Health Benefits Increase, SUN-SENTINEL, Aug. 27, 2004; Anne D'lnnocenizo, 
Employers Shift Health Costs-Workers Will Take Larger Share in 2006, COM. 
APPEAL, Sept. 14, 2005, at A3; Study Shows Impact of 6 Years of Double-Digit 
Medical Rate Increases, MANAGED CARE WKLY. DIGEST, Mar. 28, 2005, at 103. 
20 Alan Fram, Deficit Could Hit R ecord $477B, CINCINNATI POST, Jan. 26, 2004, at 
A2; Robert Pear and Edmund L. Andrews, White House Says Congressional Estimate 
of New Medicare Was Too Low, N.Y. TIMES, Feb. 2, 2004, at Al4; Staggering Hidden 
Costs of Medicare Prescriptions, NEW AMERICAN, Feb. 23, 2004, at 9; The Medicare 
Alarm, ALBANY TIMES UNION, Apr. 5, 2004, at A6. 
2
1 See Recipients Brace for Medicaid Co-Payments, CINCINNATI POST, June 27, 
2005, at KS (no author identified). 
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carte blanche to accommodate the same;
22 and the Administration has 
proposed cutting $60 billion (two percent) from Medicaid over the next 
decade. 23 The situation is disparately worse for minority groups.24 
Both the Institutes of Medicine ("IOM")
25 and the Agency for 
Healthcare Research and Quality ("AHRQ") at the Department of 
Health and Human Services ("DHH S") have documented that minority 
groups in the U.S. have significantly less access to health care, and the 
care they receive is of much lower quality. 
26 Minority groups get less 
according to forty percent of access measures and more than sixty 
percent of quality measures, and only one-fifth of this disparity is 
attributable to a decline in insurance coverage. 
27 AHRQ has 
determined that "Race and ethnicity influence a patient's chance of 
rece1vmg many specific procedures and treatments."28 Illustrations 
include: 
• "Heart disease. African Americans are 13 percent less 
likely to undergo coronary angioplasty and one-third less 
likely to undergo bypass surgery than are whites. "29 
• "Asthma. Among preschool children hospitalized for 
asthma, only 7 percent of African American children .. . , 
compared with 21 percent of white children, are prescribed 
routine medications to prevent future asthma-related 
hospitalizations. "30  
• "Breast cancer. The length of time between an abnormal 
screening mammogram and the follow-up diagnostic test to 
determine whether a woman has breast cancer is more than 
22 Id. 
23 Josh Goldstein, U.S. Medicaid Cutbacks Would Hurt States Twice, PHIL. INQUIRER, 
Feb. 8, 2005, at Cl; How Bush's Budget Goes Wrong, Bus. WK.,  Feb. 28, 2005, at 
112; Robert Pear, Governors Prepare to Fight Medicaid Cuts, N.Y. TIMES, Feb. 27, 
2005, at 27. 
24 s 
. 
ee
. g_
enerally Barbara A. Noah, The Participation of Underrepresented Minorities 
zn Clznzcal Research, 29 AM. J.L. & MED. 221 (2003)· Barbara A. Noah, Racial 
Disparities in the Delivery of Health Care, 35 SAN DIEGO L. REV. 135 (1998); 
�arbara A. Noah, Racist Health Care?, 48 FLA. L. REV. 357 (1 996). 
26 
See generally UNEQUAL TREATMENT, supra note 5. 
27 
See AHRQ Report, supra note 5; Fact Sheet, supra note 5. 
See Fact Sheet, supra note 5. 
28 See id. (emphasis added). 
29 Id. (emphasis added). 
30 Id. (emphasis added). 
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twice as long in Asian American, black, and Hispanic 
women as in white women."31 
• "Human immunodeficiency virus (HIV) infection. African 
Americans with HIV infection are less likely to be on 
antiretroviral therapy,  less likely to receive prophylaxis for 
Pneumocystis pneumonia, and less likely to be receiving 
protease inhibitors than other persons with HIV."32 
• "Nursing home care. African American residents of nursing 
homes are all far less likely than white residents to have 
sensory and communication aids, such as glasses and 
hearing aids. "33 
1011 
Exclusion of minority groups is an overarching theme in the U.S.'s 
biomedical research legacy. Exploitation is a second major theme. The 
latter is synonymous with the Tuskegee study, 34 a Public Health 
Service study which spanned four decades and traced the course of 
untreated syphilis in African American males: 
Initiated in 1932, the research targeted poor African­
American sharecroppers suffering from syphilis, but was 
presented to subjects as a study of "bad blood." The study 
continued until a July 26, 1972 New York Times story, 
"Syphilis Victims in U. S. Study Went Untreated for 40 
Years" exposed it as "the longest non-therapeutic 
experiment on human beings in medical history."35 
The study, which confirmed the apprehensions of African Americans 
and other minorities about participating in biomedical research and 
compelled an apology from the United States government under the 
31 Id. (emphasis added). 
32 Fact Sheet, supra note 5 (emphasis added). 
33 Id. (emphasis added). 
3 4  See supra note 6; D orothy E. Roberts, The Nature of Blacks' Skepticism About 
Genetic Testing, 27 SETON HALL L. REV 971, 974 (1997). See generally JAMES H. 
JONES, BAD BLOOD THE TUSKEGEE SYPHILIS EXPERIMENT (1993). 
35 PRICEWATERH;USECOOPERS LLP, INSTITUTIONAL REVIEW BOARD (IRB) 
REFERENCE BOOK 12 (Michele K. Russell-Einhorn & Thomas Puglisi eds., 200 I) 
[hereinafter IRB REFERENCE BOOK]. 
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Clinton Administration, 36 encompassed 600 men, 399 with latent 
syphilis and a control group of 201 without the disease. 3
7 These men 
were "encouraged" to participate through free meals, medical 
examinations, and burial insurance. 
38 "In a reprehensible breach of 
ethics, investigators took specific steps to ensure that subjects were 
denied access to effective treatment, even after penicillin became 
widely available, to preserve the integrity of the research."39 
Discrimination is a third major theme in the U.S.'s history of 
treatment of minorities in medicine and biomedical R&D. A notable 
and often-referenced example are the 1970s screening programs for 
sickle cell trait which resulted in employment and insurance 
discrimination against African Americans and restrictions on their 
reproductive decision-making. 40 
The absence of just representation of minority groups in 
biomedical research and the delivery of health care has been 
acknowledged by the United States Government and inspired corrective 
measures. These measures include the establishment and ongoing work 
of the AHRQ. 4 1 
II. A PROPOSAL TO BIOBANK TO WIDEN ACCESS 
FORHCHNS 
Population genetics is a means to engage in genomics and proteomics, 
the understanding of gene and protein function, respectively.42 
Genomics occupies a central position in biomedical R&D, and there is 
reason to believe that genomics will hold that position well into the 
foreseeable future.43 Bioinformatics capabilities have made it possible 
to extract extraordinary amounts of information from any given sample, 
and to process voluminous amounts of information from large numbers 
36 See id. "Finally, on May 6, 1997, nearly 20 years after the New York Times expose 
[sic] and 65 years after the Syphilis Study began, surviving subjects and the members 
of the Tuskegee Study Legacy Committee gathered at the White House to witness a 
long-awaited apology from President Clinton on behalf of the United States 
government." Id. at 13. See generally Jones, supra note 34. 
Id. at 13 (emphasis added). 
38 Id. 
39 Id. at 12-13. 
40 See generally Mark R. Farfel & Neil A. Holtzmann, Education, Consent and 
Counseling in Sickle-Cell Screening Programs: Report of a Survey, 74 AM. J. PUB. 
HEALTH 373 (1984). 
41 s 2 ee Agency for Healthcare Research and Quality (AHRQ), http://www.ahrq.gov. 
See generally Genomics Revolution supra note 8 
43 ' . 
· See generally id. 
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44 of samples. These capabilities, which continue to expand by 
multiples, are heightening demand for access to samples and 
accompanying medical information. 45 The combination of 
bioinformatics capabilities and biobanks could prove a primary means 
to make medical sense out of the map of the human genome. 46 
Some HCHNs already are gaining access to the forefront of the 
genomics revolution through technology transfer and development 
arrangements to engage in biobanking. Two of the more relevant case 
studies are biobanking initiatives by PXE International ("PXE") and 
Howard University ("Howard").47 PXE is a nonprofit foundation 
established to use biobanking to encourage researchers to study and 
develop therapies for pseudoxanthoma elasticum, a very rare hereditary 
connective tissue disorder that afflicts skin and eyes.48 Although PXE 
has adopted an aggressive IP retention policy,49 its biobank still has 
attracted a number of laboratories globally. 50 As a case study, PXE 
illustrates that, though we live in an age of academia-industry 
integration, scientific accomplishment, peer esteem, and dreams of 
Nobel prizes remain powerful influences. There are researchers who 
will embrace the means to do breakthrough research even if the quid 
pro quo for access is relinquishing financial gains from commercial 
exploitation. 
Similar to PXE, Howard University, a private university with a 
historic focus on African-Americans, has announced plans to biobank 
with the objective of influencing what research is undertaken-namely 
to encourage research on diseases with a distinguishably high incidence 
rate among those of African descent.51 Howard is gathering DNA 
samples from 25,000 people, drawing from its global alumnae network 
44 See Robert Wells, Intellectual Property/Ownership Interests, 66 LA. L. REV. 69, 73 
(2005). 
45 See generally NBAC COMMISSIONED PAPERS, supra note 12. 
46 See generally Alan E. Guttmacher & Francis S. Collins, Welcome to the Genomic 
Era, 349 NEW ENG. J. MED. 996 (2004). See also Noah, supra note 11, at 4-11; 
Malinowski, supra note 11, at 231-43. . . 
47 David E. Winickoff, Governing Population Genomics: Law, Bwethtcs and 
Biopolitics, 43 JURIMETRICS J. 187, 223 (2003). . 
48 PXE International, http://www.pxe.org (providing further information about this 
condition and PXE). 
49 Winickoff, Biopolitics, supra note 47, at 224. 
50 s 'd ee z . 
5 1 See Capstone Online, College of Medicine and First Genetic .Trust Form
 Biobank: 
Data to Advance Study of Disease Risks Among People of Afncan Descent (June 2, 
2003), http://www.howard.edu/newsevents/Capstone/2003/June/news2.htm (l
ast 
visited Jan. 14, 2006). 
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and patients at hospitals affiliated with its College of Medicine.52 
Howard is building this biobank, called the Genomic Research in the 
African Diaspora Biobank ("GRAD Biobank"), in collaboration with 
First Genetic Trust, a commercial biobanker.
53 In addition, biobanking 
already has proven a means of entry into the genomics revolution for 
the populations of Iceland and Estonia, 
54 and several other nations are 
undertakin� biobanking endeavors.55 A number of teaching hospitals 
in the U.S. 6 and the State of Utah57 are doing the same. 
Methodologies for organizing biobanks tend to be disease­
centered (e.g. , PXE58), nation-centered (e. g., deCode's biobank that 
encompasses the vast majority of  the population of Iceland59), ancestry­
centered (e. g. the International Haplotype Mapping Project ("HMP") or 
"HapMap" approach6 0), or ethnicity-centered (e.g. , Howard 
University's effort61). Avoiding explicit use of race in biobanking and 
related research may help avoid readily reverting to social and cultural 
notions of race. However, these notions are too ingrained to be 
removed from popular thought simply by avoiding the terminology, or 
even by doing so and shifting to more scientifically sound 
methodologies such as ancestry. 6 2 Consider that popular interest in 
52 Alan Pollack, Big DNA Files to Help Blacks Fight Diseases, N. Y, TIMES, May 27, 
2003, at Al, A20. 
53 First Genetic Trust, http://www.firstgenetic.net. 
54 See generally Mylene Deschenes & Clernintine S allee, Accountability in Pop ulation 
Biobanking: Comparative Approaches, 33 J.L. MED & ETHICS 40 (2005). 
55 See generally id. See also Bartha Maria Knoppers, Biobanking: International 
Norms, 33 J.L. MED&ETHICS 7, 7 (2005); Malinowski, supra note 9, at 47-50. 
56 Several major hospitals, including Duke University Medical Center, are 
collaborating with Ardais Corporation to engage in biobanking. Ardais, 
http://www.ardais.com/partners/partners.shtml. See Michael J. Malinowski, 
Technology Transfer in BioBanking: Credits, Debits and Population Health Futures, 
�? J. L. MED. & ETHIC� 54, 5? (20.05); 'Yinickoff, supra note 47, at 207. The State of Utah, m conJunction with the University of Utah and the Huntsman 
C:ancer _Foundation, has formed GenData, a non-profit corporation, to engage in 
b1obanking that utilizes the rich legacy of medical record keeping associated with 
Utah' s  Mormon community. See BARRY R. FuRROW ET AL .,  HEALTH CARE LAW 22-
23 (2003). 
�: See supra notes 47-50 and accompanying text. 
See deCode, http://www.decode.com (providing more information about the 
company). See generally Henry T. Greely, Iceland's Plan for Genomics Research: 
roacts �nd Implications, 40 JURIMETRICS J. 153 (2000). 
61 
See mfra notes 75-84 and accompanying text. 
See supra notes 47, 53-55. 
62 p rofessor Sharona Hoffman has observed that "[s]everal studies reveal that only 
half of physical anthropologists and less than one-third of cultural anthropologists 
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tracing ancestry through DNA among African Americans has been 
reported even though only a miniscule percentage of ancestral groups 
within the human species have been extensively decoded.63 Social, 
cultural, and racial identity based upon historic norms appears to be the 
inspiration.64 Scientific reality is that, especially with a legacy of 
migration, tribal integration, war, and conquests, ancestral matching for 
any individual is complicated given that contemporary population 
genetics is in its infancy and the entire human species has been decoded 
only sporadically and at the margins. 65 With only approximately 
30,000 genes in the human genome (most expectations until completion 
of the map of the human genome reached 100, 000+ active genes), 66 the 
human species is relatively young and genetically homogenous under 
present scientific standards, 67 which center largely on gene function. 68 
Genetic matches to populations yet to be decoded may prove much 
closer than matches to the very limited number of populations already 
sampled extensively and added to any particular database established at 
this time. In fact, when the human species is comprehensively decoded 
genetically, which may take many years, present experience suggests 
that categorization based upon genetic commonality may vary 
maintain that homo sapiens can be categorized by biological 'races. '" Sharona 
Hoffman, Is There a Place for "Race" as a Legal Concept?, 36 ARIZ. ST. L.J. 1093, 
1123 (2004). She also makes a strong argument for "[d]ismantling the notion of 
'race."' Id. at 1159. However, in this author's estimation, removing the terminology 
from law alone is unlikely to cause even a meaningful crack in a notion so rooted in 
culture and society at least for a generation or two. The same is likely to prove true 
even if the notion is disproved by science. 
63 See generally Amy Harmon, Blacks Pin Hope on DNA to Fill Slavery's Gaps in 
Family Trees, N.Y, TIMES, July 25, 2005, at Al, A l 7. 
64 See generally id. . . 
65 Kenneth Kidd Tensions in Process and Discovery, Remarks at Lomsiana State 
University Law Center Symposium: The Genomics Revolution? Science, Law and 
Policy (Feb. 6, 2004) (transcript on file with author). See Harmon, supra note 63, at 
Al7. 
66 Alan E. Guttrnacher & Francis S .  Collins, Genomic Medicine-A Primer, 347 NEW 
ENG. 1. MED. 1512, 1514 (2002). 
67 Human beings share 99.9 percent of these genes meaning that, with whole genes as 
the level of measure variation in the human population is just one tenth of a perc
ent. 
Moreover, 90 to 95 
'
percent of this variation appears at equal rates in every hu
man 
population. Richard S. Cooper et al., Race and Genomics, 348 NEW ENG. 1. MED. 
1166, 1167 (2003); Noah A Rosenberg et al, Genetic Structure of Human 
Populations, 298 SCIENCE 2381, 2381 (2002). 
6
8 Kid d, supra note 65. 
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significantly from cultural and social norms. 69 Fr�m. � clinical perspective, this entire exercise may prove much less s1gnif1cant than 
understanding how environmental exposures influenced by culture, 
social norms, socio-economics, and other factors interact with genetics 
to influence human health. 70 
Fortunately, there is an intense, ongoing debate over the 
scientific soundness of race-based research.71 Contrary positions were 
presented in the November 2004 issue of Nature Genetics.72 One 
position presented is that race has a genetic basis: DNA links people to 
geographic continents-regions that correspond with their self-identified 
racial classifications, and these populations have distinguishable 
genetic characteristics-such as the SCN 5 A gene carried by one in nine 
African Americans that confers a twenty-four-fold increase in sudden 
infant death syndrome ("SIDS").73 The counter position is that race 
lacks any reliable biological basis and, for meaningful science and 
medicine, links between genes and disease must be made directly rather 
than through the convoluted path cleared by social and cultural 
constructs such as race. 74 
69 See id. See generally Pilar N. Ossorio, The C oncept of Race in Social, Cultural 
and Political History, and the Potential Impact of Haplotype Mapping on the Future, 
66 LA. L. REV. 131 (2006). 
7
0 See Ossorio, Concept of Race, supra note 69 at 139-140; Richard S. Cooper et al, 
Race and Genomics, 348 NEW ENG. J. MED. 1166, 1169 ( 2003); Jonathan Kahn, 
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure 
Research, 46 PERSP. BIOLOGY & MED. 473, 480 (2003); Judith B. Kaplan & Trude 
Bennett, Use of Race and Ethnicity in Biomedical Publication, 289 JAMA 2709, 2712 
(2003); Pamela Sankar et al., Genetic Research and Health Disparities, 291 JAMA 
2985, 2987-88. 
71 . See Hoffman, supra note 62, at 1113-1128. See also David Rotman, Genes, 
Medicine, and the New Race Debate, TECH. REv., June 2003, at 41, 48, 50. 
72 See Neil Risch et al., Categorization of Humans in Biomedical Research: Genes, 
Race, and Disease 3 GENOME BIOLOGY 1, 1 (2002), available at 
�
3
ttp://genomebiology. com/ con ten t/pdf/ gb-2002-3-7 -comment2007. pdf. 
Lynn B. Jorde & Stephen P. Wooding, Genetic Variations, Classifications, and 
Race, 28 NATURE GENETICS S28, S28 (2004). See also Esteban Gonzalez Burchard 
et al., The Importance of Race and Ethnic Background in Biomedical Research and 
Clinical Practice, 348 NEW ENG. J. MED. 1170, 1171 (2003). The SNC5A discovery 
was reported in the Journal of Clinical Investigation in February, 2006. See Thomas 
H. Maugh II, Gene Raises Chance of SIDS, ADVOCATE, Feb. 2, 2006, at 4A. 
Al�ough �frican American children are three times more likely than Caucasian 
children to die from SIDS, the medical significance  of this finding is tempered by the 
fact �at SC�5A appears to count for only five percent of SIDS deaths in African 
American children. See id. 
74 See id. See also Robert S. Schwartz, Racial Profiling in Medical Research, 344 
NEW ENG. J. MED. 1392, 1392 (2001). 
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This debate is arguably being developed most effectively 
through application associated with the HapMap Project undertaken by 
the NIH, National Center for Human Genome Research Institute 
(NCHGRI), to explore the methodology of population genetics research 
based upon ancestry. 75 HMP is a collaboration among scientists and 
funding agencies from Japan, the United Kingdom, Canada, China, 
Nigeria, and the United States.76 The goal of HMP is to raise the 
concept of familial-pedigree studies up to the population level-to 
compare the genetic sequences of different individuals to identify 
chromosomal regions where genetic variants are shared.77 HMP was 
commenced in October 2002, with Stage I planned for completion in 
fall 200578 The objective of this first phase of HMP was to analyze 
DNA from populations with African, Asian, and European ancestry.79 
Stage I encompassed collection of samples from just 270 people: 
Africans (thirty sets of familial samples from the Yoruba people of 
Ibadan, Nigeria); Japanese (forty-five unrelated individuals from the 
Tokyo area); Chinese (forty-five unrelated individuals from Beijing); 
and Europeans (thirty trio samples from European-Mormon families in 
the U.S.).8 0 The sample selection was based consciously upon ancestry 
rather than any direct notions of race.8 1 Nevertheless, HMP has 
advanced with thoughtful attention to the implications of race-genetics 
connections. An ethics committee, co-chaired by Dr. Bartha Knoppers 
and Dr. Ellen Wright Clayton, has vested tremendous effort to address 
implications and develop algorithms for population genetics that 
potentially carry far beyond HMP.8 2 Professors Knoppers and Clayton 
also have made significant individual contributions by emphasizing at 
75 See HapMap Project, http://www.hapmap.org. See National Human Genome 
Research Institute, http://www.genome.gov. See generally, Ellen Wright Clayton, 
Implications for Existing Law/Regulations, 66 LA. L. REV. 125 (2006); Ossorio, supra 
note 70, at 131. 
76 See About the HapMap, http://www.hapmap.org/thehapmap.html.en. 
77 See id. See also Clayton, supra note 75, at 127; Ossorio, supra note 70, at 132-33. 
78 HapMap Project, http://www.hapmap.org. . 
79 See generally Genomics Revolution, supra note 8; HapMap Project, 
rJtp://www.hapmap.org. 
. 
See generally HapMap Project, http://www.hapmap.org. See also Ossono, supra 
note 70, at 131-142. 
81 See generally HapMap Project, http://www.hapmap.org. See also HapMap Sample 
Populations, http://www.hapmap.org/hapmappopulations.htmJ.en. . . 82 See Guidelines for Referring to the HapMap Populations in Publtcat10ns and 
Presentations, http://www.hapmap.org/citinghapmap.htrnl.en. �ee also How Are 
Ethical Issues Being Addressed?, http://www.hapmap.org/eth1calconcems.html.en 
(discussing ethics issues involving the HapMap Project). 
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conferences and in print that HMP is a pilot program to probe the 
scientific validity of ancestry-based population genetics. 83 A 
fundamental outcome of this application of population genetics is 
pragmatic identification of ethical, legal, social and other policy 
implications of the research, and pragmatic methodologies and 
algorithms sensitive to those implications have been developed. 84 
With all of the primary biobanking methodologies, including 
biobanking centered on diseases relatively more prevalent in 
populations identified as racial groups by popular cultural and social 
notions of race, there is a real possibility-arguably, a likelihood for 
the foreseeable future�f encouraging race-based medicine and race­
based research in contemporary genomics. 85 Genetic science has 
proven a powerful influence, and this influence is destined to expand 
with advancement of the field of genomics. 86 As discussed above, IOM 
and AHRQ data on treatment disparities suggest that race-based 
medicine is a present reality. 87 The data indicate that race-based 
medicine is being practiced with influences other than good science and 
to the relative detriment of non-whites.88 Moreover, there already are 
instances of race-based medicine where genomics is used to the 
detriment of non-white populations-for example, use of three loci, 
HLA A, B and D, for matching in renal transplants.89 However, there 
also are documented instances where race-based medicine is being 
reported to improve outcomes to the benefit of HCHNs-most notably, 
the FDA' s recent approval of BiDil among African Americans to 
prevent death from heart disease by lowering salt retention, and 
SCN5A screening to identify children with heightened risk of SIDS.90 
In addition, as summarized by Professor Hoffman, 
83 s ee generally Clayton, supra note 75. 
84 See generally id. ; Ossorio, supra note 70. 
85 See id. at 139-41 .  
86 See generally DOROTHY NELKIN & SUSAN LINDEE, THE DNA MYSTQUE: THE GENE 
As A CULTURAL ICON ( 1995); Sharona Hoffman, supra note 62; Michael J. 
Malinowski, Choosing the Genetic Makeup of Our Children: Our Eugenics Past­
�resent, and Future ?, 36 CONN. L. REV. 125 (2003). 
8 8  
See supra notes 25-33 and accompanying text. 
See id. 
89 C. Thomas Caskey, Haplotype Mapping and Its Applications, Remarks at Louisiana 
State University Law Center Symposium: The Genomics Revolution? Science, Law :J1d Policy (Feb. 6, 2004) (transcript on file with author). 
See supra note 73 and accompanying text (discussion of SCN5A); FDA Advisory 
Committee Recommends BiDil to Treat Black Patients with HF, CARDIOVASCULAR 
DRUG NEWS, June 17, 2005; John Pope, Heart Drug Study Triggers Questions-Test 
Results Promising for African A mericans, TIMES-PICAYUNE, Nov. 16, 2004, at A l .  It 
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Today it is believed that members of different populations 
have higher susceptibilities to different diseases and 
respond differently to certain treatments. For example, 
"racial" differences have been demonstrated with respect to 
diabetes complications, and researchers have detected 
genetic differences among "racial" groups that relate to 
HIV, Crohn '  s disease, and Alzheimer' s  disease. In 
addition, one controversial study found that black patients 
with chronic heart failure did not respond well to a 
commonly used drug, leading some doctors to stop 
providing the medication to African-American patients.91 
1 0 1 9  
Many ongoing biobanking efforts are driven by HCHNs who, 
perhaps in conjunction with the goal of commercial returns, hope to 
build a basic science floor of inclusion for their bank populations that 
may spill over into medical outcomes favoring their populations. Even 
if the science proves disappointing and these clinical applications are 
not realized, third-party use of these biobanks and resulting revenues 
and IP rights introduce resources and a possibility to improve the health 
care of the donor populations. Examples already discussed include 
biobanking by Howard University,92 deCode,93 and Estonia. 94 The 
return could be direct or through arrangements that grant HCHN­
related research institutions access to biobank users' enabling 
technologies, or perhaps even a collaborative role in the research itself. 
For national biobankers in developing economies, a possible quid pro 
quo for access might be the establishment of a domestic research 
facility. Another possibility is construction of manufacturing facilities, 
is important to note that challenges have been raised to the biological soundness of 
this FDA's BiDil decision in light of the temptation of sponsors to manipulate clinical 
data to obtain even limited market entry and, subsequently, realize much broader 
markets through off-label use. See Pope, supra, at Al.  See generally Jonathan Kahn, 
How A Drug Becomes "Ethnic ": Law, Commerce, and the Production of Racial 
Categories in Medicine, 4 YALE J. HEALTH PoL'Y, L. & ETHICS l (2005). The data 
also may have been influenced by the study's  focus on a type of he_
art disease
_ 
that 
happens to be prevalent in African Americans because of life style choices. See td. 
91  Hoffman, supra note 62, at 1 1 1 9- 1 1 20. As suggested above, such medically 
meaningful associations with groups defined by cultural and social norms may pr�ve 
more attributable to the interaction of genetics and environmental factors such as diet, 
socioeconomic background, and living conditions than genetic ancestry. See supra 
note 70 and accompanying text. 
92 s . ee supra note 47 and accompanying text. 93 s . ee supra note 92 and accompanymg text. 
M S  . ee supra note 59 and accompanymg text. 
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perhaps with incentives from entities such as the World Bank, with the 
capacity to at least satisfy domestic use of resulting commercial 
products on an at-cost basis and an obligation to do so-albeit with 
pharmaceutical sponsor oversight and host government assurances of 
full product accountability and recognition of IP rights. On the most 
pragmatic level, revenue could be generated and channeled into public 
health basics like vaccines, clean water, and sanitation. 
Admittedly, questions about the enforceability of any such 
arrangement over time invite skepticism and pessimism. However, a 
number of recent events and circumstances suggest at least an 
environment of opportunity and the possibility of a break between the 
present/future and the past. These include fuller implementation of the 
Trade Related Intellectual Property Sections ("TRIPS") of the General 
Agreement on Tariffs and Trade ("GATT");95 extensive global 
familiarity with technology transfer and development and government­
industry-academia collaborations in the life sciences; the strengthening 
of international institutions such as the World Trade Organization, 
World Bank, and World Health Organization; and international 
pressures on pharmaceutical companies and governments to close the 
life science crevasse between developed and developing economies­
all underscored by global epidemiological crises such as the threat of an 
avian flu pandemic as this article goes into print, and controversies 
such as access to AIDS drugs in African nations. 96 
Where there is commercial life science demand, there is 
opportunity. 97 This is a lesson made vividly clear by the university 
experience over the last fifteen years. With access to samples and 
medical information now at a premium and rising in value, HCHNs that 
engage in biobanking and apply technology transfer and development 
norms will have opportunities to access and reap benefits from the . 1 . 99 d genormcs revo ut10n. There are developed models, algorithms, an 
guidelines to draw from to undertake such biobanking, including some 
that address ethical, legal, and social implications in the complicated 
global setting.98 Again, this is a major HMP contribution, and the 
HMP application of population genetics encompasses working 
95 Agreement on Trade Related Aspects of Intellectual Property Rights, Apr. 15, 
1 994, Marrakesh Agreement Establishing the World Trade Organization, Annex IC, 
�egal Instruments-Results of the Uruguay Round, 33 I .L.M
. 8 1  ( 1 994). 
See generally JEFFREY SACHS, THE END OF POVERTY: ECONOMIC POSSIBILITIES FOR 
OUR TIME (2005). 
97 See Malinowski, supra note 9 at 5 1  99 ' • See generally id. 
98 See generally id. 
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knowledge of many other biobanking case studies-Iceland, Estonia, 
and so forth-and international guidelines and norms. 99 For example, 
the United Nations Educational, Scientific and Cultural Organization 
("UNESCO") has issued an International Declaration on Human 
Genetic Data,1 0 0 the Council for International Organizations of Medical 
Sciences ("CIOMS") has put forth ethical guidelines for biomedical 
research, 1 0 1 and the World Health Organization ("WHO") has 
·1 d . d 1 02 comp1 e a report on genetic atabases. Some academics also are 
providing thoughtful insights and guidance. For example, Professor 
Knoppers recently framed the global challenge of approaching 
biobanking with primarily public health norms rather than primarily  
with human subject norms that emphasize the rights of the 
individual. 1 03 An additional challenge is to expand the conceptual 
scope of public health beyond the traditional disease continuum­
prevention to treatment-to encompass R&D. 1 04 
However, assuming such global biobanking by HCHNs is even 
achievable at this time, a fundamental question lingers: Would 
embracing the opportunity to engage in biobanking other than from a 
general population, disease-centered methodology inevitably reinforce 
notions of race-based genetics and medicine? The path to reaching 
comprehensive science will be incremental, and probably will include 
some confirmations of those notions, especially until a critical mass of  
population genetics is  achieved. Although we are not genetically 
diverse relative to most other species, 1 05 our species has been impacted 
genetically through ancestry. Significant genotype-phenotype 
99 See generally Knoppers, supra note 55, at 7 - 1 4. 
IOO UNITED NATIONS EDUCATIONAL, SCIENTIFIC AND CULTURAL ORGANIZATION 
(UNESCO), INTERNATIONAL DECLARATION ON HUMAN GENETIC DATA (2003), 
available at 
portal.unesco.org/en/ . . .  &URL DO=DO_TOPIC&URL_SECTION=201 .html. 101 COUNCIL FOR INTERNATIO
-
NAL ORGANIZATION OF MEDICAL SCIENCES (CIOMS), 
lNrERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOL YING 
HUMAN SUBJECTS (2002), available at 
http://www.cioms.ch/frame guidelines_nov_2002.htm. 102 WORLD HEALTH ORGANIZATION (WHO), GENETIC DATABASES-ASSESSING THE 
BENEFITS AND THE IMPACT ON HUMAN RIGHTS AND PATIENT RIGHTS (2003), 
available at http://www. law .ed.ac. uk/ahrb/pu blications/ online/whofinalrepo
rt.rtf. 
103 55 A · t d out by Professor Parmet, the See generally Knoppers supra n ote . s pom e · . ' · · h 1 h WENDY E PARMET lntroductwn: very nature of public health is population ea t · · ' 
The . z h · L IN PUBLIC HEALTH PRACTICE Interdependency of Law and Publzc Hea t , in AW 
XXvi (Richard A. Goodman et al. eds . ,  2003) G · d 2002) 1
04 PuBuc HEALTH LAW AND ETHICS : A READER 4 (Lawrence o
. ostm e . ,  
IOS S 
• 
t t ee supra note 67 and accompanymg ex · 
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connections have been identified by working in ethnically-defined 
populations, such as the association of BRCA- 1 mutations and a form 
of breast cancer through a study focused o n  Ashkenazi Jewish women 
and the identification of the gene that causes Huntington's disease by 
studying an isolated population with an extremely high incident rate of 
the disease. 1 06 Where groups are being studied, scientists are 
identifying genetic subtleties that impact human health. 107 
Nevertheless, if the present majority opinion in the biological science 
community proves true, advancing genomics research through 
population genetics ultimately w ill  disprove many long-held notions of 
race and culture. 1 08 Present sc ience suggests no broad genetic reality 
to notions of race, especially in the absence of environmental 
influences. 109 Still, those notions are deeply rooted and, even when 
challenged by meaningful science, they are likely to linger. Aggressive 
biobanking, in addition to advancing the genomics revolution and 
introducing opportunities for HCHN s to participate, is likely to quicken 
confrontation of social-cultural notions o f  race through science in a 
comprehensive and definitive manner. 
CONCLUSION 
The U.S. has a legacy of disparity in access for minorities in both 
human health research and medicine, and that legacy lingers on. 1 10 
Now, contemporary science in the form o f  the genomics revolution, 
which has centered on population genetics and bioinformatics, 1 1 1  is 
forcing answers to one of societies' most controversial questions: Is 
there genetic reality to historic notions of race? Given that confronting 
this question is inevitable, the scientific and social agenda should be to 
move genomics forward in a responsible manner-to push through the 
present state of population genetics uncertainty into broadly meaningful 
genomics medicine, and to include more HCHNs along the way. 
Responsible biobanking is a means to advance these ambitious 
objectives, and it should be embraced accordingly. 
106 See generally Sandra Soo-Jin Lee et al., The Meaning of "Race " in the New 
Genomics: Implications for Health Disparities Research, I y ALE J. HEALTH PoL'Y, 
L. & ETHICS 33 (2001). 107 s ee, e. g., supra note 73. 
108 See generally Kidd, supra note 65. 109 s .d f ee 1 . ; c . supra note 74. 1 1 0 
1 1 1  See supra notes 18-4 1 and accompanying text. See supra notes 11- 1 2 , 43-47 and accompanying text. 
